Ranbaxy looks to add Daiichi Sankyo drugs to its Russian portfolio

While many Big Pharma players have only recently discovered the potential of doing business in Russia, India's generic drugmaker Ranbaxy Laboratories has been there for two decades. Ranbaxy has established itself by selling the low-price copycat drugs it has made its fortunes on, but is now looking at moving up the value chain.

The head of Ranbaxy's business in Russia, Aman Khanna, says Ranbaxy is looking at adding branded drugs from its Japanese parent Daiichi Sankyo to its portfolio mix in Russia. "Over the years, Ranbaxy has established itself as a preferred generic pharmaceutical company in Russia. In coming years, we look at further expanding our product portfolio to include value-added and innovator products from our parent company, Daiichi Sankyo," Khanna told The Economic Times.

The Indian company claims to have a 15.4% market share already in Russia. The company has registered 51 drugs in the Russian Federation and operates in 56 regions there. But there are developments that are making it a more challenging place to make money.

As the country works to build up its own drugmaking industry, it has told outside drugmakers they need to partner up with domestic companies and establish local production facilities to share in the spoils. It recently barred overseas suppliers of particular meds if at least two domestic alternatives are already available, which often will mean generics. The protective move is part of President Vladimir Putin's push to build up a Russian pharma industry, with 90% of "strategically important" medicines produced in-country by 2018. Currently, 85% of Russia's state drug spending goes to foreign-made drugs. In 2011, 93% of the most expensive meds sold in the country were imported. So the new tack will mean lost sales for a lot of companies.

Still, given that many Western markets are providing sluggish growth, many drugmakers see Russia and its growing market as a place they want to be. Companies like Novartis ($NVS), AstraZeneca ($AZN), GlaxoSmithKline ($GSK) and Novo Nordisk ($NVO) are among the drugmakers who are socking big money into Russian infrastructure and partnerships in a bid to capture a share of that market.

- read the Economic Times story

Related Articles:
Russia sets out limits to purchasing imported meds
Sanofi ramps up insulin production at Russian plant
Cadila Pharma selects site for $150M Russian plant

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.